Inclusion Criteria:  Subjects with intermediate and/or locally advanced HCC histologically confirmed by biopsy or by typical radiological findings. Subjects who were not suitable for or failed curative treatments such as surgical resection, local ablation therapy, transarterial chemoembolization (TACE), sorafenib, atezolizumab, bevacizumab, etc. Child-Pugh liver function class A or B. Subjects' ECOG performance status of 0 or 1. The presence of macrovascular invasion. Adequate liver, renal, and hematologic functions.  Exclusion Criteria:  Subjects who received the immune cell-based therapy within 6 months before the screening visit. Subjects with a history of a malignancy other than HCC within the last 5 years, liver transplantation, and hypersensitivity to 5-FU or cisplatin. Subjects with extra-hepatic metastases. Subjects who have ongoing autoimmune disease. Female subjects who are pregnant or lactating or women of child-bearing potential but unable to take adequate contraception.